Bromday

Eye Pain, Cataract Surgery, Conjunctivitis

Treatment

5 FDA approvals

3 Active Studies for Bromday

What is Bromday

Bromfenac

The Generic name of this drug

Treatment Summary

Bromfenac is a type of medication used to treat pain and inflammation in the eyes. It belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). These drugs are becoming more commonly used to help manage ocular pain and inflammation and can help improve surgical outcomes.

Xibrom

is the brand name

image of different drug pills on a surface

Bromday Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Xibrom

Bromfenac

2005

19

Approved as Treatment by the FDA

Bromfenac, otherwise called Xibrom, is approved by the FDA for 5 uses including Conjunctivitis and Ocular Inflammation .

Conjunctivitis

Ocular Inflammation

Eye

Helps manage Eye Pain

Eye Pain

Helps manage Eye Pain

Cataract Surgery

Helps manage Cataract Surgery

Effectiveness

How Bromday Affects Patients

Bromfenac ophthalmic solution is a medicine used to treat the eyes that is both safe and not steroid-based.

How Bromday works in the body

The way this drug works is by blocking the production of prostaglandins. Prostaglandins are responsible for causing inflammation in the eyes, like increased pressure and extra blood flow. By blocking their production, the drug helps reduce these symptoms.

When to interrupt dosage

The prescribed dose of Bromday is contingent upon the diagnosed state, such as Cataract Surgery, Eye Pain and Ocular Inflammation. The amount likewise deviates according to the technique of administration (e.g. Solution / drops - Ophthalmic or Solution / drops) specified in the table beneath.

Condition

Dosage

Administration

Cataract Surgery

, 0.9 mg/mL, 1.035 mg/mL, 0.07 %, 0.7 mg/mL, 0.76 mg/mL, 0.75 mg/mL

, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution, Suspension / drops, Suspension / drops - Ophthalmic, Solution - Ophthalmic

Eye Pain

, 0.9 mg/mL, 1.035 mg/mL, 0.07 %, 0.7 mg/mL, 0.76 mg/mL, 0.75 mg/mL

, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution, Suspension / drops, Suspension / drops - Ophthalmic, Solution - Ophthalmic

Conjunctivitis

, 0.9 mg/mL, 1.035 mg/mL, 0.07 %, 0.7 mg/mL, 0.76 mg/mL, 0.75 mg/mL

, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution, Suspension / drops, Suspension / drops - Ophthalmic, Solution - Ophthalmic

Warnings

Bromday Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Bromday.

Common Bromday Drug Interactions

Drug Name

Risk Level

Description

Valproic acid

Minor

The protein binding of Valproic acid can be decreased when combined with Bromfenac.

Aceclofenac

Moderate

The risk or severity of adverse effects can be increased when Bromfenac is combined with Aceclofenac.

Acemetacin

Moderate

The risk or severity of adverse effects can be increased when Bromfenac is combined with Acemetacin.

Acetylsalicylic acid

Moderate

The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Bromfenac.

Alclofenac

Moderate

The risk or severity of adverse effects can be increased when Bromfenac is combined with Alclofenac.

image of a doctor in a lab doing drug, clinical research

Bromday Novel Uses: Which Conditions Have a Clinical Trial Featuring Bromday?

7 active trials are assessing the potential of Bromday to alleviate Cataract Surgery, Eye Pain and Ocular Inflammation.

Condition

Clinical Trials

Trial Phases

Eye Pain

0 Actively Recruiting

Cataract Surgery

3 Actively Recruiting

Not Applicable

Conjunctivitis

0 Actively Recruiting

Patient Q&A Section about bromday

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Prolensa an NSAID?

"PROLENSA® is a nonsteroidal anti-inflammatory drug (NSAID) that is indicated to treat inflammation and reduce eye pain in patients after cataract surgery."

Answered by AI

Who makes bromday?

"The Food and Drug Administration approved Ista Pharmaceuticals' new non-steroidal anti-inflammatory drop Bromday 0.09% (bromfenac ophthalmic solution) for use after cataract surgery in October. This makes it the first q.d. NSAID approved for this indication."

Answered by AI

What is bromfenac 0. 09% used for?

"The drug Bromday, which is a solution used to drop into the eye, is intended to help with swelling and pain relief after surgery for those who have had cataracts removed."

Answered by AI

What are the side effects of Bromfenac eye drops?

"There are several potential symptoms associated with poor eye health, including blurred vision, changes in color vision, decreased vision, difficulty seeing at night, and eye pain. Other signs that something may be wrong with your eyes include red, sore eyes, sensitivity to light, and tearing. If you experience any of these symptoms, it's important to consult an eye doctor to rule out any serious problems."

Answered by AI

Clinical Trials for Bromday

Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Image of University of California, San Francisco in San Francisco, United States.

Vision Centers for Eye Care

Any Age
All Sexes
San Francisco, CA

The goal of this clinical trial is to evaluate the effect of vision centers on access to eye care and eye health outcomes in South Asia. The main questions it aims to answer are: 1. Do vision centers increase visits to eyecare centers? 2. Do vision centers increase spectacle ownership and wearing? 3. Do vision centers improve visual acuity of the population? Researchers will compare outcomes in communities randomized to have a vision center is established with communities randomized to delay establishment of a vision center. Outcomes will be assessed through population-based surveys at baseline and after two years as well as through hospital records collected throughout the study period.

Waitlist Available
Has No Placebo

University of California, San Francisco

Kieran O'Brien, PhD, MPH